1 RSV-Related Healthcare Burden: A Prospective Observational Study in a Resource-Constrained

- 2 Setting
- 3
- 4 Senjuti Saha PhD^{1#}, Sudipta Saha SM^{1,2}, Naito Kanon MSc¹, Yogesh Hooda PhD¹, Mohammad Shahidul
- 5 Islam PhD¹, Shuborno Islam BSc¹, Zabed Bin Ahmed MSc¹, Md Jahangir Alam FCPS³, Ataul Mustufa Anik
- 6 MSc¹, Probir K Sarkar FCPS³, Mohammed Rizwanul Ahsan, DCH⁴, Md. Ruhul Amin FCPS¹, Samir K Saha
- 7 PhD^{1,5}
- 8
- 9 1. Child Health Research Foundation, Dhaka, Bangladesh
- 10 2. Department of Social and Behavioural Sciences, Harvard T. H. Chan School of Public Health, Boston,
- 11 USA
- 12 3. Department of Pediatric Respiratory Medicine (Pulmonology), Bangladesh Shishu Hospital and
- 13 Institute, Dhaka, Bangladesh
- 14 4. Department of Emergency, Observatory and Referral, Bangladesh Shishu Hospital and Institute,
- 15 Dhaka, Bangladesh
- 16 5. Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
- 17
- 18 Correspondence to
- 19
- 20 Senjuti Saha, PhD
- 21 Deputy Executive Director
- 22 Child Health Research Foundation
- 23 23/3 Khilji Road, Mohammadpur
- 24 Dhaka 1207, Bangladesh
- 25 Email: senjutisaha@chrfbd.org
- 26

27 Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations globally,
 impacting overstretched health systems. Comprehensive data is vital for informing RSV vaccination
 policies.

31

Methods: From January to December 2019, a prospective study was conducted at Bangladesh's largest pediatric hospital to evaluate RSV's burden on the health system. We analyzed hospitalization rates, lengths of stay, and outcomes for children under five using WHO criteria and qPCR testing. We also examined survival probability for children denied admission due to bed shortages, compared with those admitted using the Kaplan-Meier method, and estimated the effects of a maternal vaccine using Monte-Carlo simulations.

38

Findings: Out of 40,664 children admitted, 31,692 were under five. Of these, 19,940 were eligible for 39 40 study inclusion with 7,191 meeting inclusion criteria; 6,149 (86%) had samples taken, with 1,261 (21%) 41 testing positive for RSV. The hospital incidence rate was 465 per 10,000 admissions. The median age of 42 RSV patients was 3 months, with a median stay of 5 days. RSV accounted for 8,274 bed days of the 43 total 151,110 observed bed days. In-hospital mortality was 1.9%, increasing to 9.9% during a 90-day 44 follow-up over telephone. Additionally, 9,169 children were denied admission during the study period; 45 of these, 5,969 under-five children were approached, and outcomes of 2,850 admitted versus 3,928 refused were followed. The hazard ratio for death was 1.37 for refused versus admitted children, 46 47 highest within neonates at 1.7. A 70% efficacious vaccine would equate to adding 50 hospital beds and 48 averting 195 deaths.

49

50 Interpretation: RSV significantly contributes to pediatric hospitalizations in Bangladesh, exacerbating 51 healthcare burdens and increasing mortality risks. Maternal vaccination could significantly reduce both 52 direct and indirect RSV burdens, enhancing healthcare capacity and benefiting overall child health in 53 resource-limited settings.

54

55 Funding: Bill and Melinda Gates Foundation

56 Introduction

57

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection in young
children. Annually, RSV infections are estimated to result in 33 million episodes, 3.6 million
hospitalizations, and 26,300 deaths ¹. Low- and middle-income countries (LMICs) bear a
disproportionate burden of the disease, where over 95% of RSV infections and more than 97% of RSVattributable deaths occur ¹.

63

Emerging interventions, such as maternal vaccines and long-acting monoclonal antibodies, promise to reduce RSV-related morbidity and mortality ^{2–4}. There is also growing evidence suggesting that these interventions might have broader benefits, like reducing respiratory illnesses caused by other pathogens, decreasing recurrent hospitalizations, and improving lung health ^{5–7}. Policymakers across countries are grappling with decisions about introduction, and which groups should be prioritized for these interventions. Making informed decisions necessitates up-to-date and locally relevant epidemiological data. However, there exist large data gaps from LMICs.

71

72 In Bangladesh, a densely populated lower-middle income country, with a birth cohort of almost 3 73 million⁸ the healthcare system faces unique challenges due to the high burden of communicable and 74 non-communicable diseases⁹. Data from the country's largest pediatric hospital indicate that 75 approximately 20% of children needing hospitalization—whether for communicable or noncommunicable diseases—have to be turned away due to bed shortages ¹⁰. Timely and appropriate care 76 77 is vital for child survival and well-being. In settings where healthcare resources are stretched thin, a 78 high RSV burden can exacerbate capacity issues, potentially leading to adverse health outcomes for children who cannot be admitted for various reasons. Thus, it is imperative to consider both the direct 79 80 and indirect effects of RSV infections on child health and the broader health system when making 81 informed policy decisions.

82

Two prominent multi-country studies, Aetiology of Neonatal Infections in South Asia (ANISA) ¹¹, and
 Pneumonia Etiology Research for Child Health (PERCH) ¹², have highlighted RSV as a primary etiological

85 agent in sepsis and respiratory tract infections in Bangladesh and other countries in Asia and Africa.

86 While these studies underscore RSV's role in community-based child morbidity, gaps remain in

87 understanding the extent of RSV-associated hospitalizations and the broader impact on the healthcare

88 capacity in resource-constrained settings.

89

90 To address the current gaps in data and estimate the potential impact of RSV vaccines, we conducted a 91 prospective, observational study at Bangladesh's largest pediatric hospital. We aimed to quantify RSV-92 associated hospitalizations, bed usage, and outcomes. We also assessed the wider health implications 93 for children denied admission due to bed shortages, providing crucial data to inform policy and

94 intervention strategies.

95

96 Methods

97

98 <u>Ethical considerations</u>

99 This study was approved by the ethical review board of the Bangladesh Shishu Hospital and Institute 100 (BSHI). We obtained written informed consent from guardians of children admitted in the hospital 101 from whom nasopharyngeal samples were collected. We obtained informed verbal consent from 102 caregivers when they were registered in the study after hospital admission refusal for telephone follow 103 up. We also obtained informed verbal consent from caregivers of admitted patients selected for 104 follow-up over telephone.

105

106 <u>Study Design and Setting</u>

From January to December 2019, we conducted a prospective observational surveillance at the BSHI, previously known as Dhaka Shishu Hospital (DSH), located in Dhaka, Bangladesh. BSHI, with its 653-bed capacity (2019), is Bangladesh's largest pediatric hospital. It offers primary to tertiary care for patients up to 18 years old. Admission decisions for the in-patient department (IPD) are made by physicians in the Emergency Room (ER).

- 112
- 113 This study had two main components: (i) active surveillance within the IPD to detect RSV infections;

and (ii) active surveillance of health outcomes of patients who had to be denied hospitalization due to
bed shortages in the IPD, despite needing hospitalization, and a control group of patients who were
admitted in the IPD.

117

118 <u>RSV Surveillance in the IPD</u>

119 Children aged 0–59 months admitted to the wards selected for the study with 414 beds were 120 evaluated by study physicians using the WHO RSV hospital-based surveillance case definition ¹³ (Text 121 S1, appendix page 3). The remaining 239 beds of the total 653 were not selected because they were in 122 wards that do not admit patients with possible infectious diseases (surgery, nephrology, oncology and 123 cardiology wards). Eligible children were enrolled in the study after obtaining written consent from 124 caregivers and obtaining a nasopharyngeal swab sample. Nasopharyngeal swabs were collected by 125 trained nurses and tested using established qPCR methods (Text S2, appendix page 3).

126

127 <u>Refusal Surveillance in the ER</u>

128 Upon arrival at BSHI, families with children potentially needing hospitalization are triaged to the 129 Emergency Room (ER). Here, a physician evaluates the child's condition to determine if immediate 130 hospitalization is necessary. Beds are available on a first come first serve basis. If the physician decides 131 that the child requires hospitalization, but no beds are available, families are referred or advised to 132 seek care elsewhere. During this study, when a child was refused admission due to bed shortages despite requiring hospitalization, trained research assistants documented the ER physician's diagnosis 133 134 for the patients, and upon obtaining verbal consent from the caregiver, they collected basic details, 135 including the child's age, family address, and contact numbers.

136

137 <u>Health Outcome Follow-Up</u>

Among the <5 y children refused admission due to shortage of beds and whose contact information was obtained, families were selected using a computer-based randomization algorithm, and contacted via telephone approximately 2 weeks after hospital-refusal, and the child's health status ("alive" or "deceased"), and date of death (if applicable) was recorded based on caregivers' response. If the child was alive during the 2-week follow-up, a second follow-up call was made three months post refusal. In

parallel, from the cohort of children <5 years who were admitted during the same time, children were
 randomly chosen for follow-up in the same manner. Additional information on in-hospital mortality
 was obtained from hospital records.

146

147 Survival curves were computed using the Kaplan-Meier method. Date of death was collected during follow-up, or from hospital records for admitted cases. Conservative censoring assumptions were 148 made – children refused admission and not followed-up at 14-days were considered censored at day 0, 149 and those not followed up at 90-days were considered censored at 14-days (last successful contact). 150 151 Admitted children's censoring time was dealt with similarly, except that hospital discharge (either alive 152 or through mortality) was additional information. Multivariate Cox Proportional-Hazards models were 153 used to estimate hazard ratios adjusted for diagnosis cluster (Table S1, appendix page 5), age in 154 months, and sex. We also obtained stratified estimates of hazard ratios.

155

156 *Estimated impact of RSV maternal vaccine impact analysis (Monte Carlo Simulation)*

157

158 A Monte Carlo simulation was conducted to estimate the direct and indirect effects of RSV vaccination 159 on hospital admissions and 90-day mortality. The simulation used empirical data on the total number of children requiring admission in 2019 across all age groups and diagnoses, length of stay, and 160 161 estimated 90-day survival probabilities among refused and admitted cases based on follow-up. We 162 explored the impact on total deaths within 3 months of hospital admission or refusal when a fixed 163 number of beds were occupied under a baseline scenario reflecting the empirical data. Additionally, 164 scenarios with various reductions in the number of RSV cases were simulated. The median value across 165 1000 simulations and the 95% prediction intervals are reported. Further methodological details are 166 provided in Text S3, appendix page 4.

167

168 <u>Role of funding source</u>

169 The funder had no role in study design, data collection, data analysis, data interpretation, writing of 170 the report, or the decision to submit this manuscript. The corresponding authors had full access to all 171 the data in the study and had final responsibility for the decision to submit for publication.

172	
173	Results
174	
175	Cases Hospitalized with RSV:
176	
177	In 2019, a total of 49,833 children sought care at BSHI and were advised admission, of whom 40,664
178	could be admitted based on the available beds (Figure 1, Table 1). 31,692 of them were <5, and of
179	them 19,940 were admitted in the screening wards. Of them, 7,191 met the inclusion criteria of the
180	study, and a sample was successfully collected from 6,149 (86%) of these children. Samples could not
181	be collected from the remaining 1,042 eligible cases due to various reasons including the guardian's
182	refusal to participate in the study, use of oxygen mask, and discharge before enrollment or sample
183	collection (Table S2, appendix page 5)). 92% (5658/6149) of all samples were collected within 72 hours
184	of hospitalization (Table S3, appendix page 6).
185	
186	All 6,149 samples were tested for the presence of RSV using qPCR, and of them 1,261 (21%) samples
187	tested positive. Assuming 1,042 untested eligible cases among 7191 had the same positivity as those

188 tested, the overall proportion of all hospital admissions that were RSV positive was 4.65% or 465 RSV

189 cases per 10,000 <5 hospitalizations (95% CI: 443 to 489).



190

191 Figure 1. Flowchart of sample collection and patient follow-up. The figure illustrates the process of

192 sample collection and subsequent patient follow-up for children under five admitted to BSHI or refused

admission due to unavailability of bed. Reasons for failures of sample collection and details on those

194 lost to follow-up are provided in Supplementary Appendix Tables S2, S4 - S7.

195

- 197 The highest number of patients were enrolled in the study between June and September (Figure 2A),
- and these four months accounted for over 70% of the total RSV-positive cases (882/1261) (Figure 2B).
- 199 During July, August and September, more than 20% of the 414 beds were due to RSV positive cases
- 200 (Figure 2C).
- 201

Table 1: Clinical attributes study participants enrolled in the study stratified by RSV status.

203

	Overall	RSV Negative/ Not Tested	RSV Positive	р
Number of Patients	19940	18679	1261	
Sex - Female (%)	7582 (38.0)	7196 (38.5)	386 (30.6)	<0.001
Age in months (median [IQR])	5.00 [0.00, 16.00]	5.00 [0.00, 17.00]	3.00 [1.00, 8.00]	<0.001
< 2 wks	5364 (26.9)	5293 (28.3)	71 (5.6)	
2 wks - 3 mnths	4039 (20.3)	3413 (18.3)	626 (49.6)	
4 - 6 mnths	1648 (8.3)	1464 (7.8)	184 (14.6)	
7 mnths - 2 yrs	5693 (28.6)	5381 (28.8)	312 (24.7)	
2 - 5yrs	3196 (16.0)	3128 (16.7)	68 (5.4)	
In-hospital mortality (%)	1266 (6.3)	1242 (6.6)	24 (1.9)	<0.001
Length of Stay (median [IQR])	4.00 [2.00, 7.00]	4.00 [2.00, 7.00]	5.00 [4.00 <i>,</i> 8.00]	<0.001
Diagnosis Cluster (%)				<0.001
Respiratory Manifestation	5026 (25.2)	4065 (21.8)	961 (76.2)	
Gastrointestinal Manifestation	2192 (11.0)	2178 (11.7)	14 (1.1)	
Perinatal Asphyxia	2178 (10.9)	2164 (11.6)	14 (1.1)	
Febrile Illness	1464 (7.3)	1445 (7.7)	19 (1.5)	
Systemic Infections	1421 (7.1)	1352 (7.2)	69 (5.5)	
Preterm low-birth weight	899 (4.5)	887 (4.7)	12 (1.0)	
Other	6758 (33.9)	6586 (35.3)	172 (13.6)	

204

Of the positive cases, 30.6% were females. The median age of PCR-confirmed RSV cases was 3 months
(IQR 1.3, 8.3 days) and 70% (881 of 1261) of the cases were within the first six months (Fig 3A, Table
1)). Notably, 17% of infections occurred in the first 4 weeks of life, highlighting the vulnerability of very
young babies to RSV. Median hospital stay of RSV cases was 5 days (IQR 4 – 8), and medial stay of all
RSV-negative cases and non-tested cases were 4 days (IQR 2 – 7). Throughout the year, RSV cases
accounted for 8,274 (5.5%) of the total 151,110 bed days observed.



211

212 Figure 2. RSV Infections and Bed Occupancy in BSHI in 2019. A. The total number of patients enrolled

into the study each month, and the number of samples collected from these patients. B. Percentage of

RSV positive cases detected each month. C. Percentage of occupied beds with RSV positive cases across

different months. The dip in bed occupancy seen in mid-August is because of Eid-ul-Adha holidays.

216 In total, 24 cases (1.9%) of all positive cases died during their stay at the hospital (Table 1). Median age

```
of these cases was 130 days (IQR 77 - 175) and died between 0 - 26 days of hospitalization.
```

218



219

Figure 3. Age distribution of RSV cases and length of hospital stay. A. Age distribution of RSV cases (n = 1,261) in weeks, where the green line represents RSV test positivity in different age groups, the solid orange line indicates the median age, and the dotted orange line shows the mean age. B. Length of hospital stay in days of RSV cases (n = 1,261), with the solid orange line representing the median length of stay and the dotted orange line the mean.

225 226

227 Impact of Bed Shortages on Non-Admitted Patients

228

229 During the study period, of the total 49,833 children requiring hospitalization, the hospital was unable 230 to admit 9,169 (18.4%) patients requiring admission due to lack of beds (Figure 1). Of them, we were 231 able to approach and collect contact information of 5,969 families for follow-up; 3,200 patients were not approached because they either came to the hospital at night when the study research assistants 232 233 were absent (n = 2,324) or were >5 years of age (n = 876). Of the families who provided verbal consent 234 and contact information for telephone follow-up, a random selection of 3,928 (43%) patients were 235 chosen for follow-up. Out of these, 3,435 (87%) could be successfully contacted and followed up at 2 236 weeks. The primary reasons for missing follow-up included switched-off mobile phones, incorrect 237 phone numbers, or no response to the call (Table S4, appendix page 6). During the first follow up, 2931 238 (85.3%) children were reported to be alive by their guardian, and 504 (14.7%) were reported to have 239 died. Of the 2,931 patients alive, 2631 (89.8%) could be subsequently contacted during the 3-month

follow up, and 2525 (96%) were reported to be alive, and an additional 106 (4%) had died. The survival probability at the end of follow up was 0.805 [95% CI: 0.791, 0.819] for refused patients (Figure 4a).

242







Figure 4. Survival Analysis of Patients followed-up. A. Survival probabilities of patients who were
refused admission with those who were admitted. Cases were censored at discharge if there was no
follow-up or at the last successful follow-up. B. Survival curve for only RSV-positive cases: the 24 cases
that resulted in in-hospital deaths, alongside the additional 205 cases that were followed up, of whom
18 subsequently died.

250

251 2,850 admitted <5-year children were randomly selected for follow-up during the same time. Of them, 252 2,527 (89%) were successfully followed up at 2 weeks. Reasons for unsuccessful follow up included 253 those above, in addition to missing contact information in the hospital records (Supplementary table 6). During the first follow up, 2302 (91.1%) children were reported to be healthy, and 225 (8.9%) were 254 255 reported to have died (Table 2). Of the 2,302 patients alive 1,965 (85.3%) could be subsequently 256 contacted during the 3-month follow up, of which 1,883 (95.8%) were alive, and an additional 82 257 (4.2%) had died (Figure 4). The survival probability at the end of follow up was 0.874 [95% CI: 0.861, 258 0.887] among those admitted (Figure 4a). 259

- 239
- 260
- 261
- 262

Table 2: Clinical attribute and outcome of participants admitted or refused admissions who were

followed-up. The table represents data of participants for whom data could be collected. Diagnoses
 was could not be collected for 18% of participants, 14-day mortality was missing for 12% and 90-day
 mortality was missing for 21%.

267

	Overall	Admitted	Refused	p-value
Number of Patients	6772	2845	3927	
Sex - Female (%)	2582 (38.1)	1071 (37.6)	1511 (38.5)	0.502
Age in months (median	3.00 [0.00,	4.00 [0.00,	3.00 [0.00,	0.006
[IQR])	12.00]	15.00]	11.00]	
< 2 wks	2017 (29.8)	804 (28.3)	1213 (30.9)	<0.001
2 wks - 3 mnths	1430 (21.1)	600 (21.1)	830 (21.1)	
4 - 6 mnths	622 (9.2)	226 (7.9)	396 (10.1)	
7 mnths - 2 yrs	1869 (27.6)	764 (26.9)	1105 (28.1)	
2 - 5yrs	834 (12.3)	451 (15.9)	383 (9.8)	
ER Diagnosis Cluster (%)				
Respiratory	1463 (26.5)	351 (20.1)	1112 (29.4)	
Manifestation				
Gastrointestinal	475 (8.6)	182 (10.4)	293 (7.8)	
Manifestation				
Perinatal Asphyxia	702 (12.7)	211 (12.1)	491 (13.0)	
Febrile Illness	207 (3.7)	101 (5.8)	106 (2.8)	<0.001
Systemic Infections	496 (9.0)	145 (8.3)	351 (9.3)	
Preterm low-birth	382 (6.9)	78 (4.5)	304 (8.0)	
weight				
Other	1799 (32.6)	677 (38.8)	1122 (29.7)	
14-day Mortality (%)	729 (12.2)	225 (8.9)	504 (14.7)	< 0.001
90-day Mortality (%)	917 (17.2)	307 (14.0)	610 (19.4)	<0.001

268

270	Overall comparison between the two groups revealed a hazard ratio (HR) of 1.69 (CI 1.48 - 1.94) of
271	death in children who were refused admission compared to children who were admitted (Table 3). The
272	HR was 1.37 (CI 1.56 - 1.79) in models adjusted for age, diagnosis and sex. Models stratified by age
273	groups showed that HR of death was significantly greater for refused cases among babies in their first
274	month of life (neonates) (HR 1.93 [CI 1.62 - 2.30]) but not in other age groups. When stratified by

- diagnosis, HR of death was significantly greater among those with perinatal asphyxia (HR 2.22 [1.68,
- 2.92]), systemic infections (HR 1.79 [1.13, 2.85]), and preterm low-birth weight 1.85 [1.32, 2.59].
- Table 3: Hazard ratio (HR) of refused vs admitted participants adjusted by age, sex, and diagnosis.

Adjusted by	Strata	HR [95% CI]	
		1.69 [1.48, 1.69]	
Age, Sex, Diagnosis		1.56 [1.36, 1.79]	
Sex, Diagnosis	< 1 mnth	1.93 [1.62, 2.3]	
Sex, Diagnosis	2-3 mnths	1.19 [0.89, 1.58]	
Sex, Diagnosis	4 mnths - 1 yr	1.47 [0.87, 2.48]	
Sex, Diagnosis	1-5 yrs	1.05 [0.66, 1.68]	
Age, Diagnosis	Male	1.59 [1.34, 1.9]	
Age, Diagnosis	Female	1.49 [1.2, 1.84]	
Age, Sex	Respiratory Manifestation	0.96 [0.7, 1.31]	
Age, Sex	Perinatal Asphyxia	2.22 [1.68, 2.92]	
Age, Sex	Systemic Infections	1.79 [1.13, 2.85]	
Age, Sex	Preterm low-birth weight	1.85 [1.32, 2.59]	
Age, Sex	Febrile Illness	0.79 [0.14, 4.37]	
Age, Sex	Gastrointestinal Manifestation	1.37 [0.51, 3.71]	
Age, Sex	Other	1.32 [1.02, 1.71]	

Post-hospitalization RSV-associated mortality

While the study was not designed to specifically follow-up RSV positive cases, of the 2,527 admitted children randomly selected and successfully followed up, there were 205 RSV positive cases. Of these, 18 children died within the 90-day follow-up period. Their median age was 107.5 days (IQR 44.75 - 157) Considering both in-hospital mortality of all RSV admissions and mortality during follow-up of a subset of cases revealed that survival decreased substantially over time, with a 90-day survival probability of 0.901 [95% CI: 0.865, 0.938] at the end of the follow-up period (Figure 4b).

293 Potential Impact of Maternal RSV Vaccination

294

295 In a Monte Carlo simulation of hospital admissions and refusals for the baseline scenario, based on the 296 empirical data and a 650-bed capacity, on average, 49,968 children required admissions (95% 297 prediction intervals (PI): 49,500, 50,379), and 9,221 (95% PI: 8,869, 9,760) cases were refused 298 admission over the course of the year. This was in concordance with the true burden of total cases 299 requiring admission and refusals – 49,833 and 9,169 respectively. In the vaccine scenario with 70% 300 reduction in RSV cases requiring admission, 48,895 (95% PI: 48,514, 49,315) cases required admission, 301 and 8,103 cases were refused (7,728, 8.695) – a 16.6% refusal rate. Even though total cases requiring 302 admissions in this scenario remained as high as 97.9% (48895/49968) of the baseline scenario, the number of refused cases was 87.8% (8103/9221), due to the freeing up of bed spaces. Figure 5 303 304 demonstrates the effects of a 70% reduction in RSV admissions through vaccination, showing its impact 305 on deaths and hospital bed utilization. The plot compares mortality with increase in available beds, 306 demonstrating how reducing RSV cases is akin to increasing bed capacity. Overall, there were 7,002 307 deaths (6829, 7167) in the baseline scenario, and 6807 deaths (6629, 6930) in the vaccine scenario, a 308 difference of 195 deaths. A reduction in RSV cases was found to decrease both hospital RSV incidence 309 and the overall number of RSV cases seeking admission at the hospital. The estimated reduction in 310 deaths with the 70% efficacious vaccine would be equivalent of adding roughly 50 beds to the hospital 311 although, there is considerable overlap of the variability in the estimates from the different scenarios.



313

Figure 5. Impact of RSV Vaccination on Hospital Utilization and 90-day Mortality Rates of all children

315 who require admission at BSHI. Effects of a 70% reduction in RSV admissions through vaccination,

showing its impact on deaths and hospital bed utilization among children under five. The plot

compares mortality against the effective increase in available beds, demonstrating how reducing RSV

318 cases is akin to increasing bed capacity.

319

320 Discussion

321 Informed decision-making on interventions to prevent RSV infections in young infants requires

322 contemporary and locally relevant epidemiological data. Our study demonstrates the significant impact

of RSV on healthcare resources in Bangladesh, a country characterized by a high burden of infectious

324 diseases and a substantial demand for pediatric care amidst resource limitations.

325

Our study recorded an overall RSV positivity rate of 21% among the 6,149 patients admitted to the

327 largest pediatric hospital of Bangladesh with respiratory illnesses, corresponding to an RSV hospital

328 incidence of 465 per 10,000 <5 admissions. The median age of confirmed RSV cases was 3 months.

These findings are concordant with those of the PERCH study that reported that in Bangladesh 31.2%

330 of children hospitalized with respiratory tract infections tested positive for RSV ¹².

The in-hospital mortality rate for RSV-positive cases was 1.6%, which escalated to 9.9% during the 90day follow-up of discharged patients. The median age of recorded RSV-associated deaths was 4.2 months. These data are comparable to a Zambian study that found RSV in 9% of community deaths and 5% of in-hospital deaths ¹⁴. In Child Health and Mortality Prevention Surveillance (CHAMPS) study, RSV was found in 5.5% of all deaths, with variability across countries: 9.7% in Mali, 10.7% in Ethiopia, and a lower 2% in Bangladesh ¹⁵. Half of the deaths in the CHAMPS study occurred in infants younger than six months.

339

These findings underscore the critical need for maternal immunization strategies, such as vaccines like ABRYSVO[™], which has demonstrated 81.8% efficacy in preventing RSV infections within the first three months of life ¹⁶. Our estimates suggest that maternal immunization could potentially reduce the hospital incidence from 465 to 140 cases per 10,000 <5 admissions.

344

345 Beyond the direct impact of RSV infections, our findings also demonstrate the considerable burden 346 infections impose on the healthcare system. For a minimum of three months during the study year, 347 RSV cases occupied more than 20% of the beds under observation, with a median hospital stay for RSV-348 positive cases at 5 days—longer than the overall median length of stay of 4 days for all admitted patients. In 2019, RSV cases accounted for 8,274 of the total 151,110 bed days observed. As the largest 349 350 pediatric tertiary hospital in Bangladesh, BSHI, even with its total of 653 beds, is insufficient. 351 Consequently, clinicians often must refuse admission due to bed unavailability ¹⁰. We followed over 5,000 admitted and refused children up to 90 days to determine the difference in health outcomes and 352 353 the wider effects of high-burden infections like RSV on the healthcare system. The cumulative 354 mortality proportion for children denied admission was 19.4%, significantly higher than the 14% among 355 those admitted. This discrepancy in mortality risk is guantified by a hazard ratio (HR) of 1.69 across all 356 children under five.

357

The HR for death was 1.37 among children refused admission compared to those admitted, adjusted
for age, diagnosis, and sex. The highest mortality risk was observed in neonates requiring

hospitalization within their first month of life, with a HR of 1.93. This disparity highlights the essential

role of healthcare access in determining child survival outcomes. Monte Carlo simulation using a 70%
 efficacious vaccine is estimated to be equivalent to adding approximately 50 beds to the hospital, and
 averting 195 deaths in only one hospital, each year.

364

365 The issue of bed shortages, a prevalent concern across many LMICs, is pressing. In Bangladesh, the rate 366 of 0.8 beds per 1,000 population is markedly lower than in developed nations such as 2.9 in the USA 367 and 2.5 in the UK¹⁷. With limited infrastructure, preventative strategies become even more vital. Over the past decades, the introduction of multiple vaccines in Bangladesh and improved health systems 368 369 have led to a decrease in under-5, yet the rate 33 death in 1,000 live birth remain high, underscoring the need for further disease prevention measures ¹⁸. Given the considerable proportion of hospital 370 beds occupied by RSV cases during peak periods, introducing an RSV vaccine could significantly impact 371 372 bed availability for critically ill infants. Other interventions like administration of monoclonal antibodies 373 in neonates and infants can also be considered. However, the cost and logistical hurdles associated 374 with monoclonal antibody treatments, such as nirsemivab, highlight the need for affordable, scalable, 375 and equitable solutions, particularly in LMICs like Bangladesh where 69% of health expenditures are 376 out-of-pocket ¹⁹.

377

While our 2019 study centered on RSV, a significant dengue outbreak during the same period
compounded the strain on hospital resources ²⁰. In addition, other infectious etiologies of respiratory
infections remain to be explored, as evidenced by the high number of cases meeting the inclusion
criteria for RSV October to December, despite the absence of RSV detection.

382

The findings of this study must be viewed considering certain limitations. Primary among them is the necessity to conduct the study in a single hospital due to the high volume of cases and the extensive follow-up required for thousands of patients. While the authors' lived experiences suggest that similar circumstances are likely in other resource-limited settings, a multi-site research would be helpful in developing a more detailed understanding of the RSV burden among children throughout Bangladesh and potentially the wider region. Furthermore, the study's duration was constrained to one year, shortened by the COVID-19 pandemic in the following year. A longitudinal study spanning multiple years could provide more information on the patterns of RSV seasonality, but previous reports from Bangladesh suggest an unpredictable pattern of RSV seasonality ²¹. And the overall high burden of RSV in the study hospital aligns with previous studies ^{11,12}. This study also did not investigate concurrent infections alongside RSV, nor was it set up to confirm deaths directly attributable to RSV. Lastly, potential biases due to human factors may have influenced the clinicians' admissions decisions during times of resource scarcity, even though such decisions should theoretically be unaffected by bed availability constraints.

397

The broader context and global health implications of our study are significant. The challenges highlighted related to shortage of hospital beds in places with high burden of disease are common in many LMICs and the global health community can learn from these findings particularly regarding resource allocation and estimate potential impact of preventive strategies like vaccination. This study also contributes to the growing body of evidence supporting the development and distribution of RSV vaccines or other interventions, which could significantly impact child health globally, specifically in low-resource countries where burden is the highest.

405

406 **Declaration of Interests**

407 The authors declare no conflict of interest.

408

409 Author contributions

410 S.S. contributed to conceptualization, funding acquisition, study design, implementation, monitoring, 411 data analysis, drafting the initial manuscript, and preparation of figures. S.Sa. was involved in data 412 analysis, preparation of figures, and manuscript editing. N.K. contributed to data analysis and editing. 413 Y.H. participated in data analysis, preparation of figures, and manuscript editing. M.S.I. was responsible 414 for analysis and coordination of the study, and also contributed to editing. S.I. carried out specimen 415 extraction and PCR testing. Z.B.A. coordinated and trained doctors and nurses, assisted in the 416 implementation of the study, in addition to contributing to manuscript editing. M.J.A. was involved in 417 monitoring and management activities, as well as editing. A.M.A. performed data cleaning. P.K.S. 418 contributed to management and patient data analysis. M.R.A. was involved in implementation and

- 419 management. M.R.A. contributed to editing. S.K.S. contributed to conceptualization, funding
- 420 acquisition, study design, implementation, monitoring, and manuscript editing. All authors reviewed
- 421 the manuscript and agreed on the contents.
- 422

423 Declaration of Generative AI and AI-assisted technologies in the writing process

- 424 During the preparation of this work the authors used ChatGPT to check grammar, spellings, and
- 425 improve readability of the manuscript. After using this tool/service, the authors reviewed and edited
- 426 the content as needed and take full responsibility for the content of the publication.
- 427
- 428
- 429 References

430

Li Y, Wang X, Blau DM, *et al.* Global, regional, and national disease burden estimates of acute lower
 respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a
 systematic analysis. *Lancet* 2022; **399**: 2047–64.

- Baral R, Higgins D, Regan K, Pecenka C. Impact and cost-effectiveness of potential interventions
 against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using
 a static cohort model. *BMJ Open* 2021; **11**: e046563.
- 437 3 Muller William J., Madhi Shabir A., Seoane Nuñez Beatriz, *et al.* Nirsevimab for Prevention of RSV in
 438 Term and Late-Preterm Infants. *New England Journal of Medicine* 2023; **388**: 1533–4.
- 439 4 Commissioner O of the. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in
- 440 Infants. FDA. 2023; published online Aug 22. https://www.fda.gov/news-events/press-
- 441 announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants (accessed April
 442 13, 2024).

5 Zar HJ, Nduru P, Stadler JAM, et al. Early-life respiratory syncytial virus lower respiratory tract

- 444 infection in a South African birth cohort: epidemiology and effect on lung health. *The Lancet Global*445 *Health* 2020; 8: e1316–25.
- Abreo A, Wu P, Donovan BM, *et al.* Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent
 Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. *Clin Infect Dis* 2020; **71**: 211–4.
- Feikin DR, Karron RA, Saha SK, *et al.* The full value of immunisation against respiratory syncytial virus
 for infants younger than 1 year: effects beyond prevention of acute respiratory illness. *The Lancet*
- 450 *Infectious Diseases* 2023; **0**. DOI:10.1016/S1473-3099(23)00568-6.

451 8 Bangladesh | Gavi, the Vaccine Alliance. 2018; published online Nov 29.

452 https://www.gavi.org/programmes-impact/country-hub/south-east-asia/bangladesh (accessed April
453 13, 2024).

9 Islam SMS, Uddin R, Das S, *et al.* The burden of diseases and risk factors in Bangladesh, 1990–2019: a
systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Global Health* 2023; **11**:
e1931–42.

457 10Saha S, Santosham M, Hussain M, Black RE, Saha SK. Rotavirus Vaccine will Improve Child Survival by
458 More than Just Preventing Diarrhea: Evidence from Bangladesh. *Am J Trop Med Hyg* 2018; **98**: 360–
459 3.

460 11Saha SK, Schrag SJ, El Arifeen S, *et al.* Causes and incidence of community-acquired serious

461 infections among young children in south Asia (ANISA): an observational cohort study. *The Lancet*462 2018; **392**: 145–59.

12 O'Brien KL, Baggett HC, Brooks WA, *et al.* Causes of severe pneumonia requiring hospital admission
in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *The Lancet* 2019; **394**: 757–79.

466 13Case definitions. https://www.who.int/teams/global-influenza-programme/global-respiratory 467 syncytial-virus-surveillance/case-definitions (accessed Jan 6, 2024).

468	14 Gill CJ, Mwananyanda L, MacLeod WB, et al. Infant deaths from respiratory syncytial virus in Lusaka
469	Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project. The Lancet
470	Global Health 2022; 10 : e269–77.

- 471 15 Blau DM, Baillie VL, Els T, *et al.* Deaths Attributed to Respiratory Syncytial Virus in Young Children in
- 472 High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance
- 473 (CHAMPS). *Clin Infect Dis* 2021; **73**: S218–28.
- 474 16 Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine
- 475 During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory
- 476 Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices -
- 477 United States, 2023. *MMWR Morb Mortal Wkly Rep* 2023; **72**: 1115–22.
- 478 17 World Bank Open Data. World Bank Open Data. https://data.worldbank.org (accessed April 21,
- 479 2024).
- 480 18SDG Tracker. https://sdg.gov.bd/page/indicator-wise/1/30/3/0#1 (accessed April 21, 2024).
- 481 192023-05-31-17-02-bed461250ff1b439a0338ab3ddfea682.pdf.
- 482 https://heu.portal.gov.bd/sites/default/files/files/heu.portal.gov.bd/page/364480c2_26f9_4bbb_bf
- 483 71_8b4ac613d96a/2023-05-31-17-02-bed461250ff1b439a0338ab3ddfea682.pdf (accessed April 14,
 484 2024).
- 20Yesmin S, Sarmin S, Ahammad AM, Rafi MdA, Hasan MJ. Epidemiological Investigation of the 2019
 Dengue Outbreak in Dhaka, Bangladesh. *J Trop Med* 2023; **2023**: 8898453.
- 21 Hossain ME, Rahman MZ, Islam MdM, *et al.* Pre COVID-19 molecular epidemiology of respiratory
 syncytial virus (RSV) among children in Bangladesh. *Heliyon* 2022; **8**: e11043.